We’ve seen tremendous progress in the field of cancer immunotherapy in recent years, and the potential now exists to improve on the benefits obtained with monotherapy by combining agents with complementary mechanisms of action.
More than 800 trials of immune-based combination therapies are underway; coupled with increasing opportunities for collaboration between the pharmaceutical and biotech industries, government and academia, the field is at an exciting juncture where the potential for novel therapeutic approaches has never been greater.
The Society for Immunotherapy of Cancer (SITC) Combination Immunotherapies Task Force has convened to:
The Combination Immunotherapies Task Force focus is upon the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer. Standardization of assays, assay validation, and appropriate potency assays were the subjects of one subcommittee while the other assessed the clinical utility of promising novel technologies and made recommendations on how to incorporate these into the clinical arena.
Patrick Ott, MD, PhD
Dana-Farber Cancer Institute/Harvard Medical School
[Holbrook E. Kohrt, MD, PhD*]
Stanford Cancer Institute
F. Stephen Hodi, MD
Dana-Farber Cancer Institute
Howard L. Kaufman, MD, FACS
Rutgers Cancer Institute of New Jersey
Jon M. Wigginton, MD
Jedd D. Wolchok, MD, PhD
Memorial Sloan Kettering Cancer Center
*Holbrook Edwin Kidd Kohrt, MD, PhD (1977-2016)
Dr. Kohrt had a significant impact on the field and brought his considerable scientific insights and incredible energy to every project. He was committed to the field of tumor immunology and immunotherapy and to the mission of SITC.
Journal for ImmunoTherapy of Cancer, February 2017
By summarizing the current status of combination immunotherapy, and addressing potential challenges in development and clinical implementation of combinatorial approaches, this paper provides evidence-based guidance to drive progress and improve on the clinical benefits obtained with single therapeutic agents. With greater understanding of the mechanisms of action of immunotherapy agents, and of the counter-defenses mounted by tumors, there is potential for novel combinations to increase the number of patients who respond to immunotherapy, the tolerability of treatment, and the duration of treatment response.
The cited editorial states that even with modest survival benefits, tripling of PFS as related to the PACIFIC trial of use of durvalumab immediately after chemoradiotherapy is commendable. Given minimal side effects, its addition should be considered ...
Dear Colleagues ,
Sidra Medicine is proud to host Qatar's first International Workshop on Engineered Immune Cells in Cancer Immunotherapy (EICCI): from Discovery to "Off-the shelf" Development.
Translating the potency of the anti-cancer immune ...
Dear Colleagues ,
It is our distinct pleasure to invite you to attend the Global Conference on Cancer & Oncology Research taking place at Dubai, UAE.
Date: Monday 04 and Tuesday 05 March 2019
Venue: Radisson Blu Hotel, Dubai Waterfront ...
2nd Announcement-Registration Announcement Global Conference on Cancer & Oncology Research
2019 CONFERENCE - SECOND ANNOUNCEMENT, CALL FOR ABSTRACTS AND REGISTRATION
Global Conference on Cancer & Oncology Research :
Cancer and Natural Health ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org